Peptide DatabasePage 6

265 therapeutic peptides with research summaries, clinical findings, and regulatory status.

Showing 181–216 of 265
CardiovascularResearch Phase

C-type Natriuretic Peptide (CNP)

C-type natriuretic peptide is a 22-amino acid member of the natriuretic peptide family that selectively activates natriuretic peptide receptor B…

Endogenous
CardiovascularInvestigational

Urocortin 1

Urocortin 1 is a 40-amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. It binds to both CRF receptor 1 and CRF receptor…

Intravenous
CardiovascularResearch Phase

Urocortin 2

Urocortin 2 is a 38-amino acid peptide member of the corticotropin-releasing factor family with selective affinity for CRF receptor 2. It exerts…

Intravenous
CardiovascularResearch Phase

Urocortin 3

Urocortin 3, also known as stresscopin, is a 38-amino acid peptide with high selectivity for CRF receptor 2. It produces vasodilation and increases…

Intravenous
CardiovascularInvestigational

Adrenomedullin

Adrenomedullin is a 52-amino acid peptide hormone produced by vascular endothelial and smooth muscle cells with potent vasodilatory and natriuretic…

Intravenous
CardiovascularInvestigational

Angiotensin (1-7)

Angiotensin (1-7) is a seven-amino acid peptide component of the renin-angiotensin system formed through cleavage of angiotensin II by ACE2 or from…

Subcutaneous injection, Intravenous, Oral
CardiovascularResearch Phase

Apelin-13

Apelin-13 is a 13-amino acid endogenous peptide that represents the most potent and abundant isoform of the apelin family. It acts as the ligand for…

Intravenous
OncologyFDA Approved

Degarelix (Firmagon)

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of advanced prostate cancer.…

Subcutaneous injection
OncologyFDA Approved

Triptorelin (Trelstar)

Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that functions as a long-acting GnRH agonist. Following an…

Intramuscular injection
OncologyIn Clinical Trials

Buserelin (Suprefact)

Buserelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent GnRH agonist. It binds with high…

Subcutaneous injection, Intranasal
OncologyFDA Approved

Histrelin (Vantas)

Histrelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH) that functions as a GnRH agonist. The peptide is administered…

Subcutaneous implant
OncologyFDA Approved

Abarelix (Plenaxis)

Abarelix is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It competitively blocks pituitary…

Intramuscular injection
OncologyFDA Approved

Elagolix (Orilissa)

Elagolix is a small molecule non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist administered orally. While not a peptide itself…

Oral
OncologyFDA Approved

Relugolix (Orgovyx)

Relugolix is an orally bioavailable non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist. Although it is not a peptide, it exerts…

Oral
OncologyFDA Approved

177Lu-PSMA-617 (Pluvicto)

177Lu-PSMA-617 is a radioligand therapeutic consisting of a small peptide-based ligand targeting prostate-specific membrane antigen (PSMA) conjugated…

Intravenous
OncologyFDA Approved

Somatostatin (Native)

Somatostatin is a naturally occurring cyclic tetradecapeptide hormone produced by neuroendocrine cells throughout the body, including the…

Intravenous
OncologyInvestigational

Vapreotide

Vapreotide is a synthetic octapeptide analog of somatostatin with enhanced selectivity for somatostatin receptor subtypes 2 and 5. It exerts…

Subcutaneous injection, Intravenous
OncologyIn Clinical Trials

Vantictumab

Vantictumab is a fully human monoclonal antibody that targets multiple Frizzled receptors involved in the Wnt signaling pathway. By blocking Frizzled…

Intravenous
OncologyFDA Approved

Tirbanibulin (Klisyri)

Tirbanibulin is a small molecule synthetic peptide mimetic that inhibits tubulin polymerization and disrupts Src kinase signaling pathways. It is…

Topical
OncologyIn Clinical Trials

Plitidepsin (Aplidin)

Plitidepsin is a cyclic depsipeptide originally isolated from the Mediterranean tunicate Aplidium albicans and now produced synthetically. It targets…

Intravenous
OncologyIn Clinical Trials

Melphalan Flufenamide (Pepaxto)

Melphalan flufenamide is a first-in-class peptide-drug conjugate that links the alkylating agent melphalan to a dipeptide carrier. The dipeptide…

Intravenous
GastrointestinalResearch Phase

Glucagon Receptor Antagonist Peptides

Glucagon receptor antagonist peptides are a class of molecules designed to block the glucagon receptor and prevent glucagon-mediated hepatic glucose…

Subcutaneous injection
GastrointestinalResearch Phase

Motilin

Motilin is a 22-amino acid endogenous peptide hormone secreted by enteroendocrine cells in the duodenum and jejunum. It binds to motilin receptors on…

Intravenous
GastrointestinalFDA Approved

Cholecystokinin (CCK)

Cholecystokinin is an endogenous peptide hormone existing in multiple forms, most commonly as CCK-8 and CCK-33, secreted by I-cells in the duodenum…

Intravenous
GastrointestinalResearch Phase

Gastrin

Gastrin is an endogenous peptide hormone secreted by G-cells in the gastric antrum and duodenum, existing primarily as gastrin-17 and gastrin-34. It…

Subcutaneous injection, Intravenous
GastrointestinalIn Clinical Trials

Peptide YY (PYY 3-36)

Peptide YY 3-36 is a 34-amino acid endogenous peptide hormone secreted by L-cells in the distal small intestine and colon in response to nutrient…

Intravenous, Intranasal
GastrointestinalIn Clinical Trials

Ghrelin Receptor Antagonists

Ghrelin receptor antagonists are a class of peptides and peptidomimetics designed to block the growth hormone secretagogue receptor (GHSR), also…

Subcutaneous injection, Oral
GastrointestinalResearch Phase

Guanylin

Guanylin is a 15-amino acid endogenous peptide hormone that activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. Upon…

Endogenous peptide
GastrointestinalIn Clinical Trials

Uroguanylin (Dolcanatide)

Uroguanylin is a 16-amino acid endogenous peptide structurally related to guanylin that also activates guanylate cyclase-C receptors in the…

Oral
PainResearch Phase

Dynorphin A

Dynorphin A is an endogenous opioid peptide of 17 amino acids that preferentially binds to and activates kappa-opioid receptors, though it also has…

Endogenous peptide
PainResearch Phase

Leu-Enkephalin

Leu-enkephalin is a pentapeptide (Tyr-Gly-Gly-Phe-Leu) that functions as an endogenous opioid agonist with preferential activity at delta-opioid…

Endogenous peptide
PainResearch Phase

Met-Enkephalin

Met-enkephalin is a pentapeptide (Tyr-Gly-Gly-Phe-Met) that differs from leu-enkephalin only in its C-terminal amino acid. It acts as an endogenous…

Endogenous peptide
PainResearch Phase

Endomorphin-1

Endomorphin-1 is a tetrapeptide (Tyr-Pro-Trp-Phe) that exhibits highly selective agonist activity at the mu-opioid receptor, the primary target for…

Endogenous peptide
PainResearch Phase

Endomorphin-2

Endomorphin-2 is a tetrapeptide (Tyr-Pro-Phe-Phe) that, like endomorphin-1, demonstrates highly selective agonism at mu-opioid receptors. The two…

Endogenous peptide
PainResearch Phase

Nociceptin / Orphanin FQ

Nociceptin, also known as orphanin FQ, is a 17-amino acid peptide that acts as the endogenous ligand for the nociceptin/orphanin FQ peptide (NOP)…

Endogenous peptide
PainInvestigational

Conantokin-G

Conantokin-G is a 17-amino acid peptide originally isolated from the venom of the cone snail Conus geographus. It acts as a selective antagonist of…

Intrathecal, Intravenous

All 265 peptides

Complete index — every profile, one click away.